pulmicort and Rectal-Neoplasms

pulmicort has been researched along with Rectal-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for pulmicort and Rectal-Neoplasms

Article	Year
Treatment-resistant severe capecitabine-induced diarrhoea resolved with oral budesonide. BMJ case reports, 2019, Dec-01, Volume: 12, Issue:11 Chemotherapy-induced diarrhoea (CID) is a risk of antineoplastic regimens, often associated with 5-fluorouracil (5-FU), irinotecan and capecitabine. Current treatment guidelines for CID include the use of loperamide and octreotide but do not account for other therapies, including budesonide. Small case reports have shown benefit with budesonide in CID secondary to 5-FU and irinotecan, but there is no literature base addressing budesonide use in CID secondary to capecitabine. We describe a case of a patient with severe capecitabine-induced diarrhoea that was refractory to guideline based therapy but resolved with the use of budesonide. Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Budesonide; Capecitabine; Diarrhea; Female; Glucocorticoids; Humans; Rectal Neoplasms	2019
Budesonide foam for prevention of rectal stricture following endoscopic submucosal dissection. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 2019, Volume: 31, Issue:5 Topics: Adenoma, Villous; Aged; Budesonide; Constriction, Pathologic; Endoscopic Mucosal Resection; Enema; Female; Humans; Postoperative Complications; Rectal Diseases; Rectal Neoplasms	2019

Article

Year

Treatment-resistant severe capecitabine-induced diarrhoea resolved with oral budesonide.

BMJ case reports, 2019, Dec-01, Volume: 12, Issue:11

Chemotherapy-induced diarrhoea (CID) is a risk of antineoplastic regimens, often associated with 5-fluorouracil (5-FU), irinotecan and capecitabine. Current treatment guidelines for CID include the use of loperamide and octreotide but do not account for other therapies, including budesonide. Small case reports have shown benefit with budesonide in CID secondary to 5-FU and irinotecan, but there is no literature base addressing budesonide use in CID secondary to capecitabine. We describe a case of a patient with severe capecitabine-induced diarrhoea that was refractory to guideline based therapy but resolved with the use of budesonide.

Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Budesonide; Capecitabine; Diarrhea; Female; Glucocorticoids; Humans; Rectal Neoplasms

2019

Budesonide foam for prevention of rectal stricture following endoscopic submucosal dissection.

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 2019, Volume: 31, Issue:5

Topics: Adenoma, Villous; Aged; Budesonide; Constriction, Pathologic; Endoscopic Mucosal Resection; Enema; Female; Humans; Postoperative Complications; Rectal Diseases; Rectal Neoplasms

2019